ArticleOncotarget2017
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia.Cancers · 2025Review
- The association between acute myocardial infarction and subsequent diagnosis of breast cancer: a nationwide, population-based cohort study.Scientific reports · 2024Article
- Cancer biology in diabetes update: Focusing on antidiabetic drugs.Journal of diabetes investigation · 2024Review
- Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.Diabetologia · 2023Article
- Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.Frontiers in endocrinology · 2023Article
- Review
- Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy.BMC genomic data · 2022Article
- [Metformin inhibits proliferation and promotes apoptosis of HER-2 positive breast cancer cells possibly through the Hippo-YAP pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.BMC cancer · 2022Article
- Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs.Cancer cell international · 2021Review
- Risk of cancer in long-term levothyroxine users: Retrospective population-based study.Cancer science · 2021Article
- Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer.Journal of diabetes investigation · 2020Article
- MicroRNA-27b-3p Promotes Tumor Progression and Metastasis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Triple-Negative Breast Cancer.Frontiers in oncology · 2020Article
- Type 2 Diabetes, Obesity, and Cancer Share Some Common and Critical Pathways.Frontiers in oncology · 2020Review
- Metformin as an adjuvant in breast cancer treatment.SAGE open medicine · 2019Review
- Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?Pathology oncology research : POR · 2018Review
- Article
- Sitagliptin and oral cancer risk in type 2 diabetes patients.Oncotarget · 2017Article
- Deciphering the Roles of Thiazolidinediones and PPARPPAR research · 2017Review
- Metformin Inhibits Tumorigenesis and Tumor Growth of Breast Cancer Cells by Upregulating miR-200c but Downregulating AKT2 Expression.Journal of Cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated whether rosiglitazone may affect breast cancer risk in female patients with type 2 diabetes mellitus in Taiwan. The reimbursement database of all female patients with type 2 diabetes mellitus under oral antidiabetic agents or insulin from 1996 to 2009 was retrieved from the National Health Insurance. An entry date was set on 1 January 2006 and a total of 431447 patients were followed up for breast cancer incidence till the end of 2009. Incidences for ever users, never users and subgroups of rosiglitazone dose-response parameters (tertile cutoffs of cumulative duration and cumulative dose) were calculated and hazard ratios estimated by Cox regression. There were 53029 ever users and 378418 never users, respective numbers of incident breast cancer 410 (0.77%) and 3292 (0.87%), and respective incidence 217.53 and 249.12 per 100000 person-years. The overall hazard ratio was 0.889 (95% confidence interval: 0.797-0.992) in the fully adjusted model. Significantly lower risk was observed for the third tertiles of cumulative duration (> 14 months) and cumulative dose (> 1792 mg) while compared to never users, with respective adjusted hazard ratio of 0.815 (95% confidence interval: 0.682-0.973) and 0.815 (95% confidence interval: 0.682-0.974). Additionally, a significant interaction between metformin and rosiglitazone was observed. The lowest risk was seen in patients who used both drugs (hazard ratio 0.812, 95% confidence interval: 0.705-0.934). In conclusion, rosiglitazone reduces breast cancer risk in female patients with type 2 diabetes mellitus, which shows a significant interaction with metformin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.